AIB REVIEW
By the Australian Institute of Business

Geopolitics Of Innovation: Charting A New Map for Pharmaceutical Drug Development

Dr Khalid Abubaker - Chief Operating Officer, Southern Clinical Development Consulting and Australian Institute of Business (AIB) Alumni Industry Panel (HRM) Member

AIB Review, Issue 15

Introduction

The foundational assumptions that have guided global drug development for the past thirty years are no longer valid. The established world order in biotechnology, a unipolar model where innovation and capital flowed predominantly from the West to the rest of the world, has been fractured. It is replaced by a multi-polar, politically charged landscape where national interest and scientific advancement are inextricably linked. For corporate leaders, navigating this new terrain is not an ancillary concern; it is the central strategic challenge of our time. To that end, this article provides a playbook for business leaders to navigate this new landscape, de-risk clinical development, and strategically position their organisations for growth in an era of profound global disruption.

The Policy-Profit Paradox

This new era is defined by a central, governing tension: the direct contradiction between the national security objectives of Western governments and the on-the-ground economic realities that drive corporate behaviour. On one side is the policy push for decoupling. The BIOSECURE Act powerfully illustrates this. While the bill was not enacted into law in 2024, it passed the United States (US) House of Representatives with strong bipartisan support, signalling that the issue is far from over and likely to re-emerge on the legislative agenda. Its core aim is to prevent US taxpayer funds from flowing to a list of Chinese "biotechnology companies of concern", a move that would impact hundreds of American firms. The scale of this dependency is highlighted by a 2024 survey, which revealed that 79% of responding member companies of the Biotechnology Innovation Organisation (BIO) have at least one contract with a China-based Contract Development and Manufacturing Organisation (CDMO).

On the other side is the powerful profit pull of collaboration. In stark contrast to the political rhetoric, Western pharmaceutical giants are executing a record-breaking wave of licensing agreements for innovative assets developed by Chinese biotechs. The total value of these deals surged to a five-year high of >US $41.5 billion in 2024. This dynamic, where policy pushes for divergence while science pulls for convergence, creates a high-stakes environment where a company's government relations team might lobby to mitigate the BIOSECURE Act. In contrast, its business development team negotiates a billion-dollar deal with a Chinese innovator.

Rise of the Middle Powers: New Hubs for Innovation

As the US and China clash, a strategic pathway is emerging. Savvy companies are actively de-risking their development programs by shifting critical operations to stable and efficient "middle power" nations. This pivot to countries like Australia, South Korea, and Canada is a sophisticated form of geopolitical hedging, moving a program's "jurisdictional risk" from a high-risk zone of superpower entanglement to a low-risk, predictable

environment. Australia has cemented its position as a premier destination for this de-risking strategy, offering a unique combination of financial incentives, regulatory velocity, and gold-standard data quality.

The most compelling force for the pivot to Australia is the Research and Development (R&D) Tax Incentive for eligible companies, which provides a 43.5% refundable cash-back on qualifying R&D expenditures. This is a direct cash payment from the government, not a future credit. For a capital-constrained startup, this represents a massive advantage that extends its financial runway. This incentive is coupled with exceptional regulatory speed, centred on the Clinical Trial Notification (CTN) scheme. Under this pathway, the national regulator, the Therapeutic Goods Administration (TGA), is simply notified that a trial is taking place; the primary review and approval responsibility rests with the local Human Research Ethics Committee (HREC). This streamlined process allows biotechs to move from a final protocol to first-patient-in, in as little as four to eight weeks. Crucially, this speed does not compromise quality. The Australian clinical trial ecosystem strictly adheres to the highest international standards of Good Clinical Practice (GCP). As a result, clinical trial data generated in Australia are fully and routinely accepted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), eliminating the need for duplicative early-phase trials.

Leadership In a Fractured World

Therefore, the path to the C-suite in biotech, which was once paved with deep expertise in science and finance, now requires a third core competency: geopolitical literacy. This competency involves integrating the complex interplay of international politics and economic policies into corporate strategy. The Chief Operating Officer's role is expanding from a traditional operations manager to a forward-looking geopolitical strategist, responsible for building an organisation that can thrive amidst global volatility. This means a shift in thinking from crisis response to proactive risk mitigation. Leaders borrow concepts from military planning, transforming the boardroom into a strategic "war room" to wargame potential geopolitical threats. This involves rigorously asking, "What is our contingency plan if our primary CDMO in China is added to the BIOSECURE entity list?" The response must be the development of robust and resilient supply chains, which has become a paramount strategic objective beyond simple cost optimisation.

A Leader's Playbook for the New Global Economy

The lessons from this shifting landscape apply to every business leader, regardless of industry. The required skillset has fundamentally changed. Deep expertise in your specific field is no longer enough. The modern leader must possess geopolitical literacy and translate it into practical action. Here's how:

1. **Map Your Dependencies**. Go beyond your immediate suppliers. Can you identify your supplier's suppliers (Tier 2 and Tier 3)? Where are they located geographically? Where is your customer base concentrated? Where is your company's data hosted? Visualising your operational footprint on a world map is the first step to understanding your actual exposure to political risk.
2. **Stress-Test Your Business.** Your boardroom is no longer just for spreadsheets; it's a "war room" for geopolitical strategy. Run simple tabletop exercises. What happens if tariffs are placed on a critical component from your top supplier? What if a shipping lane is disrupted for a month? What if a key market suddenly becomes politically unstable? Walking through these scenarios builds the capacity to act decisively in a real crisis.
3. **Diversify Everything.** The adage "don't put all your eggs in one basket" has never been more relevant. This means diversifying your suppliers and your customer base across different regions to hedge

against market volatility. It means diversifying your digital infrastructure to protect against cyber threats. It means building a talent pool that isn't dependent on a single location. Resilience comes from having options.

4. **Secure Your Base, Then Expand.** Before you chase growth in high-risk, high-reward markets, ensure your foundation is secure. The "Australia First" model used in drug development provides a universal playbook. Use the stability and incentives of a country like Australia to perfect your product, solidify your business model, and build a strong financial base. From this secure position, you can confidently expand globally, using your stable home base as an anchor in a volatile world.

Conclusion: A New Map of Opportunity

The global architecture of business has been permanently redrawn. The intense geopolitical competition between major world powers is the new organising principle. While the landscape is more complex, it is not indecipherable. The new map reveals a clear path to success through smart, strategic hedging into stable and supportive environments. The future will belong not to those who cling to the old atlas but to those with the foresight and agility to navigate the new one. The question every leader must now ask is: Are you ready to chart a new course?

Dr Khalid Abubaker

Chief Operating Officer, Southern Clinical Development Consulting and Australian Institute of Business (AIB) Alumni Industry Panel (HRM) Member

Khalid is the Chief Operating Officer of Southern Clinical Development Consulting, where he leads operational strategy for clinical trials. With 20 years of experience spanning pharmaceuticals, research, and business management, he specialises in navigating complex regulatory environments and optimising development pathways. As an AIB Alumni Industry Panel Member, Khalid is passionate about the intersection of business leadership, global strategy, and healthcare innovation.

Cite this article:

Abubaker, K 2025, 'Geopolitics Of Innovation: Charting A New Map for Pharmaceutical Drug Development', *AIB Review*, Issue 15.

Explore more articles from AIB Review